AbbVie invests €150m in new R&D facility in Germany
Betsy Goodfellow | May 3, 2024 | News story | Research and Development | AbbVie, Pharmacy, R&D, facility
AbbVie has announced that it is investing approximately €150m in its second largest research and development (R&D) facility worldwide. The new facility is being built at Ludwigshafen, Germany.
It is expected that the facility will be home to a state-of-the-art research and laboratory building, and will employ over 300 researchers and scientists. AbbVie has shared that the facility is being built with modern and sustainable infrastructure features, thus allowing for flexible working conditions in an attempt to enable greater scientific exchange between different areas of the business.
Martin Gastens, vice president of biologics and drug product development and managing director of R&D at AbbVie Germany, commented: “For AbbVie Germany, the new construction of our ‘LUnA’ research building is much more than a €150m investment in cutting-edge infrastructure. It is a promise for the future of AbbVie science and innovation. We are creating attractive working conditions for our top scientists and attracting new talent so that we can conduct cutting-edge research at our site in the long term […] We are very pleased that the Federal Government has taken action with the pharmaceutical strategy and has begun to make Germany a pharmaceutical location fit for the future. After all, the political framework is critical for future investment decisions.”
Rhineland Palatinate’s minister president, Malu Dreyer, added: “The German state of Rhineland-Palatinate is on track to become one of the leading hubs for biotechnology and life sciences. We support research, promote its translation and continue expanding the footprint. As the Government of the Federal State of Rhineland-Palatinate, we are proud of this additional investment made by AbbVie, and the trust which yet another large pharmaceutical company has placed in our state. We are working tirelessly on creating the best possible framework conditions for business and research, and are collaborating closely in a network with all those involved through the biotechnology advisory board and the biotechnology academy. We are actively encouraging companies to put down roots and to invest in our Federal State, and once again I’d like to express my heartfelt thanks to AbbVie for the excellent collaboration, the sharing of experiences and the great investment.”
Betsy Goodfellow
Related Content
ANGLE’s Parsortix system used in new cancer biology research
ANGLE has announced three new peer-reviewed publications demonstrating the use of its Parsortix circulating tumour …
Moderna expands use of AI-ready R&D platform
Moderna has expanded its partnership with Benchling, a cloud-based research platform, to support its broader …
Galimedix completes key stage of clinical trial for treatment targeting eye and brain diseases
Clinical biotech, Galimedix Therapeutics, has announced the completion of a single ascending dose (SAD) part …
